Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: Clinical trial news feed


Guru

Status: Offline
Posts: 523
Date:
Clinical trial news feed
Permalink  
 


 

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

 
Tuesday, June 26, 2012, 12:00:00 PM
Condition:   Hepatitis C Virus
Interventions:   Drug: Daclatasvir;   Drug: Daclatasvir;   Drug: BMS-986094;   Drug: BMS-986094;   Drug: BMS-986094;   Drug: Ribavirin;   Drug: Placebo for BMS-986094
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Suspended - verified August 2012
 

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

 
Friday, June 22, 2012, 12:00:00 PM
Condition:   Hepatitis C, Chronic
Interventions:   Drug: RO5466731;   Drug: RO5190591;   Drug: ritonavir;   Drug: ribavirin [Copegus];   Drug: RO5024048
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified August 2012
 

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

 
Monday, June 11, 2012, 12:00:00 PM
Condition:   Hepatitis C
Intervention:   Drug: Interferon-alpha
Sponsors:   University of Arizona;   University of Arizona;   Emory University;   National Center for Complementary and Alternative Medicine (NCCAM)
Active, not recruiting - verified August 2012
 

Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection

 
Thursday, June 07, 2012, 12:00:00 PM
Condition:   Chronic Hepatitis C
Intervention:   Drug: GS-7977 in combination with ribavirin
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified August 2012
 

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon -2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous Abbott Combination Study

 
Wednesday, May 30, 2012, 12:00:00 PM
Condition:   Hepatitis C (HCV), Chronic Hepatitis C
Interventions:   Drug: ABT-450/r;   Drug: ABT-267;   Drug: pegylated interferon alpha-2a (pegIFN);   Drug: Ribavirin (RBV)
Sponsors:   Abbott;   Abbott
Not yet recruiting - verified June 2012
 

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

 
Tuesday, May 29, 2012, 12:00:00 PM
Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified August 2012
 

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

 
Thursday, May 2

__________________

Do not go where the path may lead, go instead where there is no path and leave a trail.Ralph Waldo Emerson

1a - VL 22 million  F2- IL28B- CT / Inck-Riba- Peg triple therapy 9/15/12 UND 4/8/14  8 wks BT ..3/1/2013 done! 3wks Post UND

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.